<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736826</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/SB-01</org_study_id>
    <secondary_id>2014-A01120-47</secondary_id>
    <nct_id>NCT01736826</nct_id>
  </id_info>
  <brief_title>Free DNA and Nucleosome Concentrations in Pathological Pregnancies</brief_title>
  <official_title>Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that plasma concentrations of&#xD;
      nucleosomes and free DNA differ between three groups:&#xD;
&#xD;
        1. pregnant patients with complications typical of placental insufficiency or venous&#xD;
           thrombosis (group P),&#xD;
&#xD;
        2. healthy women (Group T1) and&#xD;
&#xD;
        3. healthy pregnant women (Group T2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our secondary objectives include the following:&#xD;
&#xD;
        1. To describe, in 15 healthy, non-pregnant women changes in plasma concentrations of&#xD;
           nucleosomes and free DNA over 3 months.&#xD;
&#xD;
        2. To describe, in 15 pregnant women (without complications), changes in plasma&#xD;
           concentrations of nucleosomes and free DNA over the last 7 months of pregnancy&#xD;
&#xD;
        3. To show that plasma concentrations of nucleosomes and free DNA, in patients with&#xD;
           complicated pregnancies differ according to the nature of the complication&#xD;
&#xD;
        4. To show that a relationship exists between the concentrations of nucleosomes, free DNA,&#xD;
           and total granulocyte microparticles (and trophoblast particles for pregnant women)&#xD;
&#xD;
        5. To evaluate the relationship between nucleosome concentrations, free DNA concentrations&#xD;
           and circulating leukocyte populations&#xD;
&#xD;
        6. To evaluate the relationship between nucleosome concentrations, free DNA concentrations&#xD;
           and hemostasis markers&#xD;
&#xD;
        7. To describe changes in hemostasis markers throughout pregnancy&#xD;
&#xD;
        8. To evaluate the relationship between nucleosome concentrations, free DNA concentrations&#xD;
           and the angiogenic marker CD146&#xD;
&#xD;
        9. To add to the Nîmes University Hospital biological collections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">137</enrollment>
  <condition>Pregnancy</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Hypertension, Pregnancy-Induced</condition>
  <condition>Eclampsia</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Pre-Eclampsia</condition>
  <condition>Fetal Death</condition>
  <condition>Placental Insufficiency</condition>
  <arm_group>
    <arm_group_label>Group P: pregnancy w/complications</arm_group_label>
    <description>The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).&#xD;
100 patients will be included.&#xD;
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T1: Healthy volunteers</arm_group_label>
    <description>Healthy volunteers with no history of chronic or neoplastic disease.&#xD;
30 healthy volunteers will be included.&#xD;
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T2: Pregnancy, no complications</arm_group_label>
    <description>Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.&#xD;
50 pregnant volunteers will be included.&#xD;
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
    <description>15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.&#xD;
Interventions to be administered: Blood work, Months 1 &amp; 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
    <description>15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.&#xD;
Interventions to be administered: Bloodwork, Months -1 to -6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bloodwork, baseline</intervention_name>
    <description>36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group P: pregnancy w/complications</arm_group_label>
    <arm_group_label>Group T1: Healthy volunteers</arm_group_label>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
    <arm_group_label>Group T2: Pregnancy, no complications</arm_group_label>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood work, Months 1 &amp; 2</intervention_name>
    <description>36 ml of blood are drawn at 1 &amp; 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bloodwork, Months -1 to -6</intervention_name>
    <description>36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At each visit a total of 36 ml of blood will be drawn (5 x EDTA tube = 5 x 4.5ml; 2 x CTAD&#xD;
      tube = 2 x 4.5 ml and 1 dry tube = 4.5 ml).&#xD;
&#xD;
      Tubes will be rapidly conditioned and samples stored at -80°C. After analysis, remaining&#xD;
      samples will be stored in the Nîmes University Hospital Biological Collections.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes three groups:&#xD;
&#xD;
        Group P: 100 pregnant women with complications typical of placental vascular disease or&#xD;
        venous thromboembolism.&#xD;
&#xD;
        Group T1: 30 non-pregnant, healthy volunteers&#xD;
&#xD;
          -  The first 15 patients from group T1 will form group T1x. The latter group has two&#xD;
             months of additional follow up.&#xD;
&#xD;
        Group T2: 50 pregnant, healthy volunteers&#xD;
&#xD;
          -  The first 15 patients from group T2 will form group T2x. The latter group has 7 months&#xD;
             of follow-up during pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for all patients:&#xD;
&#xD;
          -  The patient must have given her informed and signed consent&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
        Inclusion Criteria for patients in group P:&#xD;
&#xD;
          -  The patient is pregnant and has complications typical of placental vascular disease&#xD;
             (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal&#xD;
             death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism)&#xD;
&#xD;
        Inclusion Criteria for patients in group T1:&#xD;
&#xD;
          -  The patient is available for 3 months of follow-up&#xD;
&#xD;
          -  The patient is a non-pregnant healthy volunteer&#xD;
&#xD;
          -  No identifiable chronic pathologies&#xD;
&#xD;
          -  No history of neoplastic disease&#xD;
&#xD;
          -  No history of chronic infectious disease&#xD;
&#xD;
          -  No acute disease (such as benign infection), now or within the past two weeks&#xD;
&#xD;
        Inclusion Criteria for patients in group T2:&#xD;
&#xD;
          -  The patient is available for 7 months of follow-up&#xD;
&#xD;
          -  The patient is pregnant, with no identifiable pregnancy complications&#xD;
&#xD;
          -  No identifiable chronic pathologies&#xD;
&#xD;
          -  No history of neoplastic disease&#xD;
&#xD;
          -  No history of chronic infectious disease&#xD;
&#xD;
          -  No acute disease (such as benign infection), now or within the past two weeks&#xD;
&#xD;
        Exclusion Criteria for all patients:&#xD;
&#xD;
          -  The patient is participating in another study (with the exception of the following&#xD;
             studies: PAPILLO-PMA (2013-A00538-37), ElastoMAP (2013-A01148-37), ElastoDéclenche&#xD;
             (2014-A00828-39), LXRs (2009-A00968-49), Bakri (2013-A00914-41), OASIS 2&#xD;
             (2013-A00022-43)).&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the patient&#xD;
&#xD;
          -  The patient cannot read French&#xD;
&#xD;
          -  The patient is receiving hormonal ovarian stimulation in the context of medically&#xD;
             assisted procreation&#xD;
&#xD;
          -  Impossible to perform venipuncture under good conditions&#xD;
&#xD;
          -  New complication or pathology during the study (except for pregnancy complications in&#xD;
             group P)&#xD;
&#xD;
        Exclusion Criteria for group P:&#xD;
&#xD;
          -  Twin or multiple pregnancy&#xD;
&#xD;
          -  The patient is participating in another study (with the exception of those mentioned&#xD;
             in the exclusion criteria for all patients and the DG Postpartum study&#xD;
             (2013-A00277-38)&#xD;
&#xD;
        Exclusion Criteria for group T1:&#xD;
&#xD;
          -  The patient is pregnant&#xD;
&#xD;
          -  The patient is breast feeding&#xD;
&#xD;
          -  The patient has given birth within the last 3 months&#xD;
&#xD;
          -  Known history of chronic disease&#xD;
&#xD;
          -  History of treated neoplastic disease&#xD;
&#xD;
          -  Acute disease within the past two weeks (includes benign disease)&#xD;
&#xD;
        Exclusion Criteria for group T2:&#xD;
&#xD;
          -  Pregnancy with complications&#xD;
&#xD;
          -  Known history of chronic disease&#xD;
&#xD;
          -  History of treated neoplastic disease&#xD;
&#xD;
          -  Acute disease within the past two weeks (includes benign disease)&#xD;
&#xD;
          -  Twin or multiple pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Bouvier, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eve Mousty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plasma nucleosome concentration</keyword>
  <keyword>plasma free DNA concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Placental Insufficiency</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

